JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Julia Qin maintains an Overweight rating on Guardant Health (NASDAQ:GH) and raises the price target from $45 to $48.
August 08, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Julia Qin maintains an Overweight rating on Guardant Health and raises the price target from $45 to $48.
The Overweight rating and increased price target from a reputable analyst at JP Morgan is likely to positively influence investor sentiment and drive short-term price appreciation for Guardant Health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100